Ujeong Bio Animal Testing Laboratory Achieves Full AAALAC Accreditation

[Asia Economy Reporter Lee Chun-hee] Woojung Bio announced on the 8th that the Woojung Bio New Drug Cluster (Wooshin Cluster) animal facility has obtained 'Full Accreditation' from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

AAALAC is the world's most prestigious international certification organization for the humane and scientific management of preclinical animal experiments. Over 1,000 research institutions including pharmaceutical and bio companies, universities, and hospitals in 50 countries worldwide have received this certification. The Wooshin Cluster animal facility is the first privately operated shared animal facility in Korea to obtain AAALAC accreditation. This achievement follows the designation of the facility as an Excellent Animal Experiment Facility (KELAF) by the Ministry of Food and Drug Safety in Korea last February.

The company explained that during the on-site inspection, the remote digital behavior experiment system ‘DVC®’ and the fully automated robot cleaning system received favorable evaluations. DVC® is equipment that produces continuous behavioral data 24 hours a day, 365 days a year, and is a preclinical testing platform established in preparation for the increasing demand for the development of treatments for degenerative brain diseases such as Alzheimer's.

Woojung Bio stated that by recently succeeding in obtaining consecutive certifications, it has strengthened its competitiveness in the field of preclinical trials. In particular, preclinical trial data conducted at AAALAC-accredited institutions are known to be advantageous for recognition as IND (Investigational New Drug) application materials by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company plans to leverage these strengths to actively market to pharmaceutical and bio companies that have previously used overseas Contract Research Organizations (CROs).

Cheon Byeong-nyeon, CEO of Woojung Bio, said, “From the planning stage of the Wooshin Cluster, we envisioned and realized a world-class animal testing facility,” adding, “We will expand our business targeting the global new drug development market, including Asia, based on this AAALAC accreditation.”

This content was produced with the assistance of AI translation services.